$PULM
Pulmatrix, Inc.

2018 Q1 Form 10-K Financial Statement

#000119312518080793 Filed on March 13, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 2016 Q4
Revenue $153.0K $335.0K $120.0K
YoY Change -59.88% -57.14%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.050M $7.570M $1.840M
YoY Change 25.0% -5.61% -12.38%
% of Gross Profit
Research & Development $3.221M $10.24M $2.770M
YoY Change 92.64% 0.9% 12.15%
% of Gross Profit
Depreciation & Amortization $60.00K $246.0K $70.00K
YoY Change -6.25% -1.6% 40.0%
% of Gross Profit
Operating Expenses $5.267M $17.81M $4.610M
YoY Change 59.03% -30.7% 0.88%
Operating Profit -$5.114M -$17.48M
YoY Change 54.41% -29.72%
Interest Expense $106.0K $643.0K -$230.0K
YoY Change -43.32% -27.01% 4.55%
% of Operating Profit
Other Income/Expense, Net -$1.000K -$581.0K -$70.00K
YoY Change -106.25% 28950.0% 250.0%
Pretax Income -$5.220M -$18.06M -$12.79M
YoY Change 50.0% -41.38% 181.72%
Income Tax $0.00 -$2.960M
% Of Pretax Income
Net Earnings -$5.221M -$18.06M -$9.830M
YoY Change 49.9% -35.15% 116.52%
Net Earnings / Revenue -3412.42% -5389.85% -8191.67%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.384M -$9.309M -$6.597M
COMMON SHARES
Basic Shares Outstanding 22.28M shares 14.70M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.550M $3.550M $4.180M
YoY Change -85.29% -15.07% -77.88%
Cash & Equivalents $1.553M $3.550M $4.182M
Short-Term Investments
Other Short-Term Assets $350.0K $700.0K $580.0K
YoY Change -14.63% 20.69% 181.55%
Inventory
Prepaid Expenses
Receivables $153.0K
Other Receivables $0.00
Total Short-Term Assets $2.052M $4.250M $4.759M
YoY Change -81.27% -10.71% -76.74%
LONG-TERM ASSETS
Property, Plant & Equipment $554.0K $610.0K $786.0K
YoY Change -23.27% -22.78% 14.74%
Goodwill $10.91M $10.91M
YoY Change 0.0% -31.54%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K $200.0K
YoY Change 0.0% 0.0% -20.0%
Total Long-Term Assets $11.67M $11.73M $11.90M
YoY Change -1.42% -1.43% -51.24%
TOTAL ASSETS
Total Short-Term Assets $2.052M $4.250M $4.759M
Total Long-Term Assets $11.67M $11.73M $11.90M
Total Assets $13.72M $15.98M $16.66M
YoY Change -39.79% -4.08% -62.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.192M $460.0K $747.0K
YoY Change 407.23% -38.67% -31.47%
Accrued Expenses $2.479M $2.160M $1.317M
YoY Change 72.27% 63.64% -11.37%
Deferred Revenue
YoY Change
Short-Term Debt $2.520M $0.00 $0.00
YoY Change
Long-Term Debt Due $2.524M $3.220M $2.586M
YoY Change -5.15% 24.32% 151.31%
Total Short-Term Liabilities $6.196M $5.840M $4.650M
YoY Change 42.93% 25.59% 28.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $3.217M
YoY Change -100.0% -100.0% -43.48%
Other Long-Term Liabilities $0.00 $40.00K
YoY Change -100.0% 300.0%
Total Long-Term Liabilities $0.00 $0.00 $3.217M
YoY Change -100.0% -100.0% -43.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.196M $5.840M $4.650M
Total Long-Term Liabilities $0.00 $0.00 $3.217M
Total Liabilities $6.200M $5.840M $7.902M
YoY Change -10.04% -26.08% -35.58%
SHAREHOLDERS EQUITY
Retained Earnings -$179.2M -$155.9M
YoY Change 12.42% 21.73%
Common Stock $186.8M $164.7M
YoY Change 6.51% 2.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.528M $10.14M $8.761M
YoY Change
Total Liabilities & Shareholders Equity $13.72M $15.98M $16.66M
YoY Change -39.79% -4.08% -62.87%

Cashflow Statement

Concept 2018 Q1 2017 2016 Q4
OPERATING ACTIVITIES
Net Income -$5.221M -$18.06M -$9.830M
YoY Change 49.9% -35.15% 116.52%
Depreciation, Depletion And Amortization $60.00K $246.0K $70.00K
YoY Change -6.25% -1.6% 40.0%
Cash From Operating Activities -$3.125M -$14.48M -$2.500M
YoY Change 4.52% 9.34% -16.11%
INVESTING ACTIVITIES
Capital Expenditures $74.00K -$20.00K
YoY Change -83.74% -86.67%
Acquisitions
YoY Change
Other Investing Activities $0.00 $20.00K
YoY Change -100.0%
Cash From Investing Activities -$74.00K $10.00K
YoY Change -82.79% -107.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.847M
YoY Change -80.96%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.128M 13.92M -640.0K
YoY Change -87.94% -1425.62%
NET CHANGE
Cash From Operating Activities -3.125M -14.48M -2.500M
Cash From Investing Activities -74.00K 10.00K
Cash From Financing Activities 1.128M 13.92M -640.0K
Net Change In Cash -1.997M -632.0K -3.130M
YoY Change -131.4% -95.71% 0.32%
FREE CASH FLOW
Cash From Operating Activities -$3.125M -$14.48M -$2.500M
Capital Expenditures $74.00K -$20.00K
Free Cash Flow -$14.55M -$2.480M
YoY Change 6.25% -12.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22280160 shares
CY2017Q2 dei Entity Public Float
EntityPublicFloat
47823941
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18902000
CY2015Q4 us-gaap Goodwill
Goodwill
15943000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
32606000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1086000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1317000
CY2016Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
54000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
4759000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2671000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
164706000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
747000
CY2016Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
206000
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
796000
CY2016Q4 us-gaap Assets
Assets
16663000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4182000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14850526 shares
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14850526 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2016Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
46000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
50031000
CY2016Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
5803000
CY2016Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
136000
CY2016Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
107000
CY2016Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
35000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2862000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2493000
CY2016Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2016Q4 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
350000
CY2016Q4 us-gaap Goodwill
Goodwill
10914000
CY2016Q4 us-gaap Liabilities
Liabilities
7902000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16663000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4650000
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2586000
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3217000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13000
CY2016Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
43455000
CY2016Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
58000
CY2016Q4 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
50031000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
577000
CY2016Q4 us-gaap Prepaid Insurance
PrepaidInsurance
197000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
786000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3457000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
204000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-155946000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2829301 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.89
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
8761000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1172000
CY2016Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
15000
CY2016Q4 pulm Prepaid Clinical Trials
PrepaidClinicalTrials
9000
CY2016Q4 pulm Accrued End Of Term Fee
AccruedEndOfTermFee
155000
CY2016Q4 pulm Deferred Tax Assets Deferred Expense Capitalized Startup
DeferredTaxAssetsDeferredExpenseCapitalizedStartup
1221000
CY2016Q4 pulm Accrued Clinical And Consulting Current
AccruedClinicalAndConsultingCurrent
202000
CY2016Q4 pulm Accrued Legal And Patent Current
AccruedLegalAndPatentCurrent
51000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2162000
CY2017Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
57000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
4246000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2870000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
184137000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
457000
CY2017Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1000
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1113000
CY2017Q4 us-gaap Assets
Assets
15978000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3550000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21047498 shares
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21047498 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2017Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
68000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
38969000
CY2017Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
3221000
CY2017Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
35000
CY2017Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
27000
CY2017Q4 us-gaap Deposits Money Market Deposits
DepositsMoneyMarketDeposits
51000
CY2017Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
81449000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2377000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
131774000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2789000
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2017Q4 us-gaap Deferred Tax Liabilities Undistributed Foreign Earnings
DeferredTaxLiabilitiesUndistributedForeignEarnings
0
CY2017Q4 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
47000
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4407000
CY2017Q4 us-gaap Goodwill
Goodwill
10914000
CY2017Q4 us-gaap Liabilities
Liabilities
5841000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15978000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5840000
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3221000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
70000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
676000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2028000
CY2017Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
32820000
CY2017Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
44000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
654000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
698000
CY2017Q4 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
38969000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
696000
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
203000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
614000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3484000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
204000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-174002000
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.69
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3646249 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1803612 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.21
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3695634 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.69
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
10137000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1109000
CY2017Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
3000
CY2017Q4 pulm Prepaid Clinical Trials
PrepaidClinicalTrials
421000
CY2017Q4 pulm Debt Instrument Accretion Of Debt Discount
DebtInstrumentAccretionOfDebtDiscount
101000
CY2017Q4 pulm Accrued End Of Term Fee
AccruedEndOfTermFee
225000
CY2017Q4 pulm Unrestricted Cash
UnrestrictedCash
3600000
CY2017Q4 pulm Deferred Tax Assets Deferred Expense Capitalized Startup
DeferredTaxAssetsDeferredExpenseCapitalizedStartup
983000
CY2017Q4 pulm Accrued Clinical And Consulting Current
AccruedClinicalAndConsultingCurrent
568000
CY2017Q4 pulm Working Capital Deficit
WorkingCapitalDeficit
1600000
CY2017Q4 pulm Accrued Legal And Patent Current
AccruedLegalAndPatentCurrent
61000
CY2015Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2016-12-31
CY2015Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-12-31
CY2015 pulm Fair Value Of Warrant Derivative Liabilities At Issuance Recorded As Debt Discount
FairValueOfWarrantDerivativeLiabilitiesAtIssuanceRecordedAsDebtDiscount
11000
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7065325 shares
CY2017 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
12000
CY2017 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
12000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2818000
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentrations of Credit Risk</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Cash is a financial instrument that potentially subjects the Company to concentrations of credit risk. For all periods presented, substantially all of the Company&#x2019;s cash was deposited in an account at a single financial institution that management believes is creditworthy. The Company is exposed to credit risk in the event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. The Company maintains its cash at a high quality financial institution and has not incurred any losses to date.</p> </div>
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-632000
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2017 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
12000
CY2017 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
2695000
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
246000
CY2017 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
34000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
246000
CY2017 us-gaap Depreciation And Amortization Discontinued Operations
DepreciationAndAmortizationDiscontinuedOperations
47000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Type
DocumentType
10-K
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.613 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.031 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.009 pure
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.050 pure
CY2017 dei Entity Registrant Name
EntityRegistrantName
Pulmatrix, Inc.
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001574235
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.977 pure
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7567000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18056000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
754000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-290000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
119000
CY2017 us-gaap Interest Expense
InterestExpense
643000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-74000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14477000
CY2017 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1 Segment
CY2017 us-gaap Operating Expenses
OperatingExpenses
17810000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13919000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-18056000
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-17475000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
28000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
74000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
304000
CY2017 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
-2695000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10243000
CY2017 us-gaap Revenues
Revenues
335000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
2818000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
2805000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
90597 shares
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M7D
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.19
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M23D
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.34
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.04
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y9M3D
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1095355 shares
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
138425 shares
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19371564 shares
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-11062000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16310000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
304000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
59000
CY2017 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
122000
CY2017 dei Trading Symbol
TradingSymbol
PULM
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payments, estimating fair value of equity instruments recorded as derivative liabilities, estimating the useful lives of depreciable and amortizable assets, valuation allowance against deferred tax assets, goodwill impairment, and estimating the fair value of long-lived assets to assess whether impairment charges may apply.</p> </div>
CY2017 pulm Cash Restricted For Letter Of Credit
CashRestrictedForLetterOfCredit
153000
CY2017 pulm Noncash Rent Expense
NoncashRentExpense
21000
CY2017 pulm Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
16310000
CY2017 pulm Intrinsic Value Of Common Stock Warrants Outstanding
IntrinsicValueOfCommonStockWarrantsOutstanding
0
CY2017 pulm Non Cash Interest Expenses
NonCashInterestExpenses
171000
CY2017 pulm Fair Value Of Warrant Derivative Liabilities At Issuance Recorded As Debt Discount
FairValueOfWarrantDerivativeLiabilitiesAtIssuanceRecordedAsDebtDiscount
1000
CY2017 pulm Fair Value Adjustment On Derivative Liability
FairValueAdjustmentOnDerivativeLiability
-34000
CY2017 pulm Deferred Tax Assets Tax Credit Carryforwards Expiration Date Description
DeferredTaxAssetsTaxCreditCarryforwardsExpirationDateDescription
Various dates from 2022 through 2037.
CY2017 pulm Operating Loss Carryforwards Expiration Date Description
OperatingLossCarryforwardsExpirationDateDescription
Various dates from 2023 through 2037.
CY2017 pulm Operating Lease Agreement Amended Date
OperatingLeaseAgreementAmendedDate
2015-10-27
CY2017 pulm Effective Income Tax Rate Reconciliation Nondeductible Expense Permanent Differences
EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferences
-0.003 pure
CY2017 pulm Effective Income Tax Rate Reconciliation Writedown Of Intangible Asset
EffectiveIncomeTaxRateReconciliationWritedownOfIntangibleAsset
0.000 pure
CY2017 pulm Effective Income Tax Rate Reconciliation Nondeductible Expense Interest
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterest
-0.001 pure
CY2017 pulm Revenue From Technology Access Fees
RevenueFromTechnologyAccessFees
1000000
CY2017 pulm Transition Tax
TransitionTax
0
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6204179 shares
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2827000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-14720000
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2016 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
16000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
250000
CY2016 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-24000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2356000
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2959000
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-603000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
250000
CY2016 us-gaap Depreciation And Amortization Discontinued Operations
DepreciationAndAmortizationDiscontinuedOperations
184000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.88
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.096 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.202 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.030 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.007 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.043 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000 pure
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-82000
CY2016 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
5029000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8015000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30802000
CY2016 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
7534000
CY2016 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
4575000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-312000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2959000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-346000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
86000
CY2016 pulm Noncash Rent Expense
NoncashRentExpense
43000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-983000
CY2016 us-gaap Interest Expense
InterestExpense
881000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-431000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13243000
CY2016 us-gaap Operating Expenses
OperatingExpenses
25701000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-1046000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-27843000
CY2016 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
2000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-24866000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
455000
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
24000
CY2016 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
-1046000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10152000
CY2016 us-gaap Revenues
Revenues
835000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
3998000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
3998000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M6D
CY2016 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1171000
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14815230 shares
CY2016 pulm Impairment Of Intangible Assets Excluding Goodwill After Tax
ImpairmentOfIntangibleAssetsExcludingGoodwillAfterTax
4575000
CY2016 pulm Cash Restricted For Letter Of Credit
CashRestrictedForLetterOfCredit
153000
CY2016 pulm Noncash Or Part Noncash Acquisition Fixed Assets Acquired Trade In Value
NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue
60000
CY2016 pulm Non Cash Interest Expenses
NonCashInterestExpenses
212000
CY2016 pulm Fair Value Adjustment On Derivative Liability
FairValueAdjustmentOnDerivativeLiability
24000
CY2016 pulm Effective Income Tax Rate Reconciliation Nondeductible Expense Permanent Differences
EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferences
-0.005 pure
CY2016 pulm Effective Income Tax Rate Reconciliation Writedown Of Intangible Asset
EffectiveIncomeTaxRateReconciliationWritedownOfIntangibleAsset
0.056 pure
CY2016 pulm Effective Income Tax Rate Reconciliation Nondeductible Expense Interest
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterest
-0.001 pure

Files In Submission

Name View Source Status
0001193125-18-080793-index-headers.html Edgar Link pending
0001193125-18-080793-index.html Edgar Link pending
0001193125-18-080793.txt Edgar Link pending
0001193125-18-080793-xbrl.zip Edgar Link pending
d481342d10k.htm Edgar Link pending
d481342dex211.htm Edgar Link pending
d481342dex231.htm Edgar Link pending
d481342dex311.htm Edgar Link pending
d481342dex312.htm Edgar Link pending
d481342dex321.htm Edgar Link pending
d481342dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pulm-20171231.xml Edgar Link completed
pulm-20171231.xsd Edgar Link pending
pulm-20171231_cal.xml Edgar Link unprocessable
pulm-20171231_def.xml Edgar Link unprocessable
pulm-20171231_lab.xml Edgar Link unprocessable
pulm-20171231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending